Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06220864 as recruiting, last updated 2026-06-25. Enrolment is 400 planned participants, an estimate. Interventions: SNV1521, DB-1310, Abiraterone, Darolutamide. Primary measures include Safety of SNV1521; Tolerability of SNV1521. No results are posted in the registry; this does not exclude separate publications.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/